Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism

Study on the Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica and Gene Polymorphism: a Cohort Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04601142

Enrollment

350

Registered

2020-10-23

Start date

2020-10-31

Completion date

2021-12-31

Last updated

2020-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gene, Glucocorticoid Resistance, Neuromyelitis Optica

Brief summary

Aims of this study are to observe the correlation between ABCB1、VDR、TBX21、NR3C1 and other gene polymorphisms and the effect of glucocorticoid shock therapy on neuromyelitis optica. Investigators plan to include patients with neuromyelitis optica who will receive glucocorticoid shock therapy prospectively. The patients are divided into glucocorticoid sensitive (GS) group and glucocorticoid resistance (GR) group according to the change of central vision after treatment. Patients' clinical data will be collected and blood samples are needed for single nucleotide polymorphism (SNP) typing test. Through statistical analysis, the data differences between GS group and GR group were compared, and the effects of clinical indexes and gene polymorphisms on the efficacy of glucocorticoid shock therapy in the treatment of neuromyelitis optica should be analyzed.

Interventions

DRUGMethylprednisolone

methylprednisolone pulse therapy: 500-1000mg/d，３-５ｄ

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of neuromyelitis optica * Chinese Han nationality, gender is unlimited; * Must be able to accept methylprednisolone pulse therapy

Exclusion criteria

* Other optic nerve diseases, such as ischemic, compressive, invasive, traumatic, toxic and nutritional metabolic, hereditary optic neuropathy; * Visual path and central lesion on optic chiasma; * Other eye diseases, such as anterior segment lesions, retinopathy, macular lesions, ametropia, glaucoma, etc; * Non-organic visual impairment; * Treated with glucocorticoid in two weeks.

Design outcomes

Primary

Measure	Time frame	Description
the change of best corrected visual acuity (BCVA)	3 day after the treatment of methylprednisolone pulse therapy	Test BCVA before and after the treatment of methylprednisolone pulse therapy, and calculate the change value

Countries

China

Contacts

Primary ContactYu yang Dai, PhD

daiyy1991@163.com010-58268486

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026